These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17275512)

  • 1. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
    Takami A; Mochizuki K; Ito S; Sugimori C; Yamashita T; Asakura H; Okumura H; Nakao S
    Transplant Proc; 2007; 39(1):237-9. PubMed ID: 17275512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
    Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
    Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Takasugi K; Iseki T; Tojo A; Asano S
    Bone Marrow Transplant; 2008 Feb; 41(4):371-6. PubMed ID: 17982495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
    Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
    Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
    Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
    Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
    Ljungman P; Oberg G; Aschan J; Ehrnst A; Lönnqvist B; Pauksen K; Sulila P
    Bone Marrow Transplant; 1996 Sep; 18(3):565-8. PubMed ID: 8879618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
    Parente F; Bianchi Porro G
    Am J Gastroenterol; 1998 Mar; 93(3):317-22. PubMed ID: 9517631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
    Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
    Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.